﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Tabriz University of Medical Sciences</PublisherName>
      <JournalTitle>Medical Journal of Tabriz University of Medical Sciences</JournalTitle>
      <Issn>2783-2031</Issn>
      <Volume>34</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2012</Year>
        <Month>06</Month>
        <DAY>12</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>Comparing the Efficacy of Topical Terbinafine 1% Cream with Topical Ketoconazole 2% Cream and Placebo in the Treatment of Facial Seborrhoeic Dermatitis</ArticleTitle>
    <FirstPage>103</FirstPage>
    <LastPage>108</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>
        </FirstName>
        <LastName>Hamideh Herizchi</LastName>
      </Author>
      <Author>
        <FirstName>
        </FirstName>
        <LastName>Shahla Babaie Nejad</LastName>
      </Author>
      <Author>
        <FirstName>
        </FirstName>
        <LastName>Sara Saniee</LastName>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">
      </ArticleId>
    </ArticleIdList>
    <History>
      <PubDate PubStatus="received">
        <Year>2012</Year>
        <Month>06</Month>
        <Day>12</Day>
      </PubDate>
    </History>
    <Abstract>Background and Objectives: Previous uncontrolled trials have suggested that topical terbinafine 1% cream could be useful in the treatment of seborrhoeic dermatitis. The aim of the present study was to evaluate the clinical efficacy of topical terbinafine 1% cream in patients with facial seborrhoeic dermatitis.  Materials and Methods: Ninety outpatients with seborrheic dermatitis were randomized into three groups: topical terbinafine 1% cream (n=30), topical ketoconazole 2% cream (n=30), and placebo (n=30). The patients received one of these treatments twice daily for 4 weeks. Clinical evaluation of erythema, scaling and itching, each scored on a 0-3 scale was recorded at weeks 0, 4, and 12. Results: At baseline, the mean total clinical score was 5.04±2.02, 5.04±1.50 and 4.97±1.71 in the terbinafine, ketoconazole and placebo groups, respectively. At week 12, the mean total clinical score was 1.78±2.47, 1.81±2.43 and 3.73±1.74 in the terbinafine, ketoconazole and placebo groups, respectively. A significant decrease in the mean total clinical score was found in the terbinafine and ketoconazole groups compared with the placebo group (P=0.003), while response to terbinafine was not significantly different from that to the ketoconazole (P&gt;0.05). Conclusion: Terbinafine 1% cream had a comparable efficacy and safety profile to that of ketoconazole 2% cream in the treatment of facial seborrheic dermatitis.</Abstract>
  </Article>
</ArticleSet>